ArticleAsian Pacific journal of cancer prevention : APJCP2025
Role of microRNA-486-5p as Biomarker Response in Cell Line K562 of Chronic Myeloid Leukemia.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.Asia-Pacific journal of clinical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to evaluate the efficiency and accuracy of microRNA (miR)-486-5p as a screening and diagnostic tool for chronic myeloid leukemia (CML).
methodsThe study was performed on K562 cell line. The cell line of the erythroleukemia type originated from a 53-year-old female patient suffering from chronic myelogenous leukemia during a blast crisis. The cells are non-adherent, rounded in shape, and positive for the BCR: ABL1 fusion gene. In addition, we measured the expression of miR-486-5p in peripheral blood monocytes from healthy volunteers and compared the result with Imatinib treated and untreated K562 cell line.
resultAs compared to control blood cells from healthy volunteers, there was a statistically significant downregulation of the expression of miR-486-5p in untreated K562 cells (p-value = 0.007). After Imatinib exposure, the miR-486-5p expression was significantly upregulated in K562 cells as compared to treated and untreated K562 cells (p-value = 0.004).
conclusionNumerous reports demonstrate the role of miRNA in acting as oncogenes or tumor suppressors in various cancers. We have reported an alteration in the expression of miR-486-5p in the CML cell line. The upregulation of miR-486-5p expression in the post-imatinib exposure K562 cell line suggests that miR-486-5p has an onco-suppressor effector role in the BCR-ABL downstream signalling pathway. It is possible to investigate miR-486-5p as a potential biomarker for early CML detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.